|
1
|
Yang Q, Lang C, Wu Z, Dai Y, He S, Guo W,
Huang S, Du H, Ren D and Peng X: MAZ promotes prostate cancer bone
metastasis through transcriptionally activating the KRas-dependent
RalGEFs pathway. J Exp Clin Cancer Res. 38:3912019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhu Z, Wen Y, Xuan C, Chen Q, Xiang Q,
Wang J, Liu Y, Luo L, Zhao S, Deng Y and Zhao Z: Identifying the
key genes and microRNAs in prostate cancer bone metastasis by
bioinformatics analysis. FEBS Open Bio. 10:674–688. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hu ZD, Jiang Y, Sun HM, Wang JW, Zhai LL,
Yin ZQ and Yan J: KIF11 Promotes proliferation of hepatocellular
carcinoma among patients with liver cancers. Biomed Res Int.
2021:26767452021. View Article : Google Scholar
|
|
4
|
Peng P, Chen T, Wang Q, Zhang Y, Zheng F,
Huang S, Tang Y, Yang C, Ding W, Ren D, et al: Decreased miR-218-5p
levels as a serum biomarker in bone metastasis of prostate cancer.
Oncol Res Treat. 42:165–185. 2019. View Article : Google Scholar
|
|
5
|
Wang M, Xia F, Wei Y and Wei X: Molecular
mechanisms and clinical management of cancer bone metastasis. Bone
Res. 8:302020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang X: Interactions between cancer cells
and bone microenvironment promote bone metastasis in prostate
cancer. Cancer Commun (Lond). 39:762019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sathianathen NJ, Koschel S, Thangasamy IA,
Teh J, Alghazo O, Butcher G, Howard H, Kapoor J, Lawrentschuk N,
Siva S, et al: Indirect comparisons of efficacy between combination
approaches in metastatic hormone-sensitive prostate cancer: A
systematic review and network meta-analysis. Eur Urol. 77:365–372.
2020. View Article : Google Scholar
|
|
8
|
Boevé L, Hulshof M, Vis AN, Zwinderman AH,
Twisk JWR, Witjes WPJ, Delaere KPJ, van Moorselaar RJA, Verhagen
PCMS and G van Andel: Effect on survival of androgen deprivation
therapy alone compared to androgen deprivation therapy combined
with concurrent radiation therapy to the prostate in patients with
primary bone metastatic prostate cancer in a prospective randomised
clinical trial: Data from the HORRAD trial. Eur Urol. 75:410–418.
2019. View Article : Google Scholar
|
|
9
|
Teo MY, Rathkopf DE and Kantoff P:
Treatment of advanced prostate cancer. Annu Rev Med. 70:479–499.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Reis LO: Metastasis-free survival-progress
or lowering the bar on nonmetastatic prostate cancer. Eur Urol.
74:682–683. 2018. View Article : Google Scholar
|
|
11
|
Kuzma M and Kliment J: Metastasis-free
survival as a new endpoint in castration-resistant prostate cancer.
Bratisl Lek Listy. 121:411–414. 2020.PubMed/NCBI
|
|
12
|
Xie W, Regan MM, Buyse M, Halabi S,
Kantoff PW, Sartor O, Soule H, Clarke NW, Collette L, Dignam JJ, et
al: Metastasis-free survival is a strong surrogate of overall
survival in localized prostate cancer. J Clin Oncol. 35:3097–3104.
2017. View Article : Google Scholar
|
|
13
|
Wang Y, Smallwood PM, Williams J and
Nathans J: A mouse model for kinesin family member 11
(Kif11)-associated familial exudative vitreoretinopathy. Hum Mol
Genet. 29:1121–1131. 2020. View Article : Google Scholar
|
|
14
|
Li TF, Zeng HJ, Shan Z, Ye RY, Cheang TY,
Zhang YJ, Lu SH, Zhang Q, Shao N and Lin Y: Overexpression of
kinesin superfamily members as prognostic biomarkers of breast
cancer. Cancer Cell Int. 20:1232020. View Article : Google Scholar
|
|
15
|
Daigo K, Takano A, Thang PM, Yoshitake Y,
Shinohara M, Tohnai I, Murakami Y, Maegawa J and Daigo Y:
Characterization of KIF11 as a novel prognostic biomarker and
therapeutic target for oral cancer. Int J Oncol. 52:155–165.
2018.
|
|
16
|
Piao XM, Byun YJ, Jeong P, Ha YS, Yoo ES,
Yun SJ and Kim WJ: Kinesin family member 11 mRNA expression
predicts prostate cancer aggressiveness. Clin Genitourin Cancer.
15:450–454. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Apte RS, Chen DS and Ferrara N: VEGF in
signaling and disease: Beyond discovery and development. Cell.
176:1248–1264. 2019. View Article : Google Scholar
|
|
18
|
Murukesh N, Dive C and Jayson GC:
Biomarkers of angiogenesis and their role in the development of
VEGF inhibitors. Br J Cancer. 102:8–18. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Garcia J, Hurwitz HI, Sandler AB, Miles D,
Coleman RL, Deurloo R and Chinot OL: Bevacizumab
(Avastin®) in cancer treatment: A review of 15 years of
clinical experience and future outlook. Cancer Treat Rev.
86:1020172020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Melegh Z and Oltean S: Targeting
angiogenesis in prostate cancer. Int J Mol Sci. 20:26762019.
View Article : Google Scholar
|
|
21
|
Cai C, Wang H, He HH, Chen S, He L, Ma F,
Mucci L, Wang Q, Fiore C, Sowalsky AG, et al: ERG induces androgen
receptor-mediated regulation of SOX9 in prostate cancer. J Clin
Invest. 123:1109–1122. 2013. View
Article : Google Scholar
|
|
22
|
Roudier MP, Winters BR, Coleman I, Lam HM,
Zhang X, Coleman R, Chéry L, True LD, Higano CS, Montgomery B, et
al: Characterizing the molecular features of ERG-positive tumors in
primary and castration resistant prostate cancer. Prostate.
76:810–822. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kumar A, Coleman I, Morrissey C, Zhang X,
True LD, Gulati R, Etzioni R, Bolouri H, Montgomery B, White T, et
al: Substantial interindividual and limited intraindividual genomic
diversity among tumors from men with metastatic prostate cancer.
Nat Med. 22:369–378. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee H, Lee M, Byun SS, Lee SE and Hong SK:
Evaluation of prostate cancer stage groups updated in the 8th
edition of the American joint committee on cancer
tumor-node-metastasis staging manual. Clin Genitourin Cancer.
17:e221–e226. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Epstein JI, Egevad L, Amin MB, Delahunt B,
Srigley JR and Humphrey PA; Grading Committee, : The 2014
international society of urological pathology (ISUP) consensus
conference on gleason grading of prostatic carcinoma: Definition of
grading patterns and proposal for a new grading system. Am J Surg
Pathol. 40:244–252. 2016. View Article : Google Scholar
|
|
26
|
Berish RB, Ali AN, Telmer PG, Ronald JA
and Leong HS: Translational models of prostate cancer bone
metastasis. Nat Rev Urol. 15:403–421. 2018. View Article : Google Scholar
|
|
27
|
Fizazi K, Shore N, Tammela TL, Ulys A,
Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, et
al: Nonmetastatic, castration-resistant prostate cancer and
survival with darolutamide. N Engl J Med. 383:1040–1049. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Talapatra SK, Anthony NG, Mackay SP and
Kozielski F: Mitotic kinesin Eg5 overcomes inhibition to the phase
I/II clinical candidate SB743921 by an allosteric resistance
mechanism. J Med Chem. 56:6317–6329. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Even-Ram S, Doyle AD, Conti MA, Matsumoto
K, Adelstein RS and Yamada KM: Myosin IIA regulates cell motility
and actomyosin-microtubule crosstalk. Nat Cell Biol. 9:299–309.
2007. View
Article : Google Scholar
|
|
30
|
Venere M, Horbinski C, Crish JF, Jin X,
Vasanji A, Major J, Burrows AC, Chang C, Prokop J, Wu Q, et al: The
mitotic kinesin KIF11 is a driver of invasion, proliferation, and
self-renewal in glioblastoma. Sci Transl Med. 7:304ra1432015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nomiri S, Karami H, Baradaran B,
Javadrashid D, Derakhshani A, Nourbakhsh NS, Shadbad MA, Solimando
AG, Tabrizi NJ, Brunetti O, et al: Exploiting systems biology to
investigate the gene modules and drugs in ovarian cancer: A
hypothesis based on the weighted gene co-expression network
analysis. Biomed Pharmacother. 146:1125372022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Carmeliet P and Jain RK: Molecular
mechanisms and clinical applications of angiogenesis. Nature.
473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ferrara N: VEGF as a therapeutic target in
cancer. Oncology. 69 (Suppl 3):S11–S16. 2005. View Article : Google Scholar
|
|
34
|
Zhao Y, Cai C, Zhang M, Shi L, Wang J,
Zhang H, Ma P and Li S: Ephrin-A2 promotes prostate cancer
metastasis by enhancing angiogenesis and promoting EMT. J Cancer
Res Clin Oncol. 147:2013–2023. 2021. View Article : Google Scholar
|
|
35
|
Bono AV, Celato N, Cova V, Salvadore M,
Chinetti S and Novario R: Microvessel density in prostate
carcinoma. Prostate Cancer Prostatic Dis. 5:123–127. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ioannidou E, Moschetta M, Shah S, Parker
JS, Ozturk MA, Pappas-Gogos G, Sheriff M, Rassy E and Boussios S:
Angiogenesis and anti-angiogenic treatment in prostate cancer:
Mechanisms of action and molecular targets. Int J Mol Sci.
22:99262021. View Article : Google Scholar
|
|
37
|
Tarantino G, Crocetto F, Vito CD, Martino
R, Pandolfo SD, Creta M, Aveta A, Buonerba C and Imbimbo C:
Clinical factors affecting prostate-specific antigen levels in
prostate cancer patients undergoing radical prostatectomy: A
retrospective study. Future Sci OA. 7:FSO6432021. View Article : Google Scholar : PubMed/NCBI
|
